Total Payments
$202,688
2024 Payments
$64,858
Companies
7
Transactions
43
Payment Breakdown by Category
Research$122,528 (60.5%)
Consulting$78,304 (38.6%)
Travel$1,290 (0.6%)
Food & Beverage$565.29 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $122,528 | 10 | 60.5% |
| Consulting Fee | $78,304 | 28 | 38.6% |
| Travel and Lodging | $1,290 | 2 | 0.6% |
| Food and Beverage | $565.29 | 3 | 0.3% |
Payments by Type
Research
$122,528
10 transactions
General
$80,160
33 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $120,300 | 3 | $0 (2019) |
| Glaukos Corporation | $71,217 | 25 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $5,844 | 7 | $0 (2018) |
| Roche TCRC, Inc. | $2,875 | 2 | $0 (2018) |
| Perrigo Company plc | $1,728 | 2 | $0 (2019) |
| Padagis US LLC | $700.35 | 3 | $0 (2021) |
| Ocular Therapeutix, Inc. | $24.35 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $64,858 | 19 | Glaukos Corporation ($64,858) |
| 2023 | $6,359 | 6 | Glaukos Corporation ($6,359) |
| 2021 | $700.35 | 3 | Padagis US LLC ($700.35) |
| 2019 | $9,028 | 3 | Bausch Health US, LLC ($7,300) |
| 2018 | $116,658 | 4 | Bausch Health US, LLC ($113,000) |
| 2017 | $5,086 | 8 | Novartis Pharmaceuticals Corporation ($4,986) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $3,960.14 | General |
| 12/19/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $3,248.32 | General |
| 12/19/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $267.00 | General |
| 12/04/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $299.88 | General |
| 10/23/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $1,157.71 | General |
| 10/23/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $356.71 | General |
| 09/18/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $6,051.82 | General |
| 09/18/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $978.82 | General |
| 08/14/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $9,433.11 | General |
| 08/14/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $3,822.37 | General |
| 07/03/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $3,826.64 | General |
| 07/03/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $3,692.61 | General |
| 06/19/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $2,224.64 | General |
| 06/12/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $6,583.69 | General |
| 05/08/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $5,516.75 | General |
| 04/10/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $3,159.68 | General |
| 03/06/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $4,833.23 | General |
| 03/06/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $4,094.71 | General |
| 03/06/2024 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 12/20/2023 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $780.12 | General |
| 11/08/2023 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $3,089.88 | General |
| 11/01/2023 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $119.88 | General |
| 10/18/2023 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $299.88 | General |
| 02/01/2023 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $1,559.88 | General |
| 02/01/2023 | Glaukos Corporation | — | Consulting Fee | Cash or cash equivalent | $509.04 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Masked, Active-Controlled, Parallel Group, Multi-Center Bioequivalence Study of the Generic Brinzolamide 1 Ophthalmic Suspension Compared to Reference Listed Drug Azopt Brinzolamide Ophthalmic Suspension 1 in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension. | Bausch Health US, LLC | $113,000 | 2 |
| A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PARALLEL GROUP, MULTI-CENTER BIOEQUIVELENCE STUDY OF THE GENERIC BRINZOLAMIDE 1 OPHTHALMIC SUSPENSION COMPARED TO BRANDED BRINZOLAMIDE 1 OPHTHALMIC SUSPENSION AZOPT IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION | Bausch Health US, LLC | $7,300 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,528 | 4 |
| Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Brimonidine Ophthalmic Suspension 1 percent to Simbrinza in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes | Padagis US LLC | $700.35 | 3 |
About Dr. Kenneth Sall, MD
Dr. Kenneth Sall, MD is a Ophthalmology healthcare provider based in Artesia, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/18/2008. The National Provider Identifier (NPI) number assigned to this provider is 1578749685.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Sall, MD has received a total of $202,688 in payments from pharmaceutical and medical device companies, with $64,858 received in 2024. These payments were reported across 43 transactions from 7 companies. The most common payment nature is "" ($122,528).
Ad
Practice Information
- Specialty Ophthalmology
- Location Artesia, CA
- Active Since 01/18/2008
- Last Updated 10/16/2017
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1578749685
Products in Payments
- BRINZOLAMIDE (Drug) $113,000
- AZOPT (Drug) $7,300
- BEOVU (Drug) $4,288
- Non-Covered Product (Drug) $2,800
- SIMBRINZA (Biological) $1,528
- ReSure Sealant (Device) $24.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.